Roxanne Jozaei, Mohammad-Ali Javadi, Iman Safari, Afrooz Moghaddasi, Sepehr Feizi, Mozhgan Rezaei Kanavi, Sajad Najafi, Bahareh Safdari, Iman Salahshourifar, Elahe Elahi, Fatemeh Suri
Journal: Ophthalmic genetics 2022;43(4):496-499
PMID: 35473478
PURPOSE
Transforming growth factor beta-induced ()-associated corneal dystrophies (CDs) are a clinically heterogeneous group of CDs caused by mutations in the gene. Nucleotide sequences encoding two arginine residues at positions 124 and 555 in TGFBI protein are mutation hotspots. We screened regions of that include the hotspots in a cohort of Iranian patients with -associated CDs. We also performed a meta-analysis for frequencies of all reported mutations.
METHODS
Twenty-four -associated CD-diagnosed patients were recruited. Exons 4 and 12 of were amplified by the polymerase chain reaction and sequenced by Sanger protocol. A meta-analysis on reported sequence data was done by reviewing all published relevant articles available in NCBI.
RESULTS
Twenty-two out of 24 patients had mutations in exons 4 or 12 of . The most frequent mutations were p.Arg124Cys, p.Arg124His, and p.Arg555Trp; each of these was found in six families. Three other missense mutations including p.Arg555Gln, p.Ile522Asn, and p.Ala546Thr were also identified. The data suggested a fairly tight genotype/phenotype correlation for the most common CDs. Literature review evidenced that the reported mutations affected less than 30% of the amino acids of the TGFBI protein and that p.Arg124His, p.Arg124Cys, p.Arg555Trp, p.Arg124Leu, p.Arg555Gln, and p.His626Arg were the most frequent mutations.
CONCLUSION
mutation profile of Iranian patients is very similar to that of the rest of the world. The meta-analysis confirmed the worldwide prevalence of p.Arg124 and p.Arg555, showed that p.His626Arg is also relatively frequent, and evidenced the value of screening exons 4 and 12 of .
Other Literature Sources:
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.